"杏輝"貝他每麗軟膏

国家: 台湾

语言: 中文

来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有效成分:

BETAMETHASONE DIPROPIONATE;;SALICYLIC ACID

可用日期:

杏輝藥品工業股份有限公司 宜蘭縣冬山鄉中山村中山路84、84之4、84之6、84之7號、冬山鄉中山村新寮路95、95之1、100之7、100之13、100之15、100之16、103、136號 (42042734)

ATC代码:

D01AE20

药物剂型:

軟膏劑

组成:

BETAMETHASONE DIPROPIONATE (6804000220) 0.64MG; SALICYLIC ACID (8428000700) 30MG

每包单位数:

塑膠罐裝;;鋁管裝

类:

製　劑

处方类型:

須由醫師處方使用

厂商:

杏輝藥品工業股份有限公司 宜蘭縣冬山鄉中山村中山路８４號 TW

治疗领域:

combinations

疗效迹象:

慢性異位性皮膚炎、神經性皮膚炎（單純苔癬）、牛皮癬、濕疹、扁平苔癬、頭皮皮脂漏皮膚炎、汗皰、尋常性魚鱗癬等發炎症狀之解除

產品總結:

有效日期: 2028/05/25; 英文品名: BETASAY OINTMENT "SINPHAR"

授权日期:

1998-05-25

资料单张

Betamethasone dipropionate
Salicylic acid
Betamethasone Dipropionate.............0.64mg
(eq. to Betamethasone..................... 0.50mg)
Salicylic Acid......................................30mg
White Petrolatum
Liquid Petrolatum
(
)
1.
1~2
2.
60gm
25
PIC/S GMP
BETASAY
Ointment
(Anti-inflammatory Agent)
042269
G-6310
1000
8 4
SINPHAR PHARMACEUTICAL CO., LTD.
84, CHUNG SHAN ROAD, CHUNG SHAN VILLAGE, TUNG - SHAN SHINE, I - LAN,
TAIWAN
[phone]
website
h t t p
//www.sinphar.com
R
PIC/S GMP
Betamethasone dipropionate,a synthetic corticosteroid , is
effective in the treatment of corticosteroid responsive dermatoses
because of their anti-inflammatory , anti-pruritic , and
vasoconstrictive
actions. The addition of salicylic acid exerts a keratolytic on the
epidermis.
Composition
Each gm Contains
Betamethasone Dipropionate.............0.64mg
(eq. to Betamethasone..................... 0.50mg)
Salicylic Acid......................................30mg
Other ingredients
White Petrolatum
Liquid Petrolatum
Indications
Chronic ectopic dermatitis, neurodermatitis, psoriasis,
eczema,lichen planus, seborrheic dermatitis of scalp,
pompholyx ,ichthyosis vulgaris.
Dosage and Administration
1. Apply thinly 1~2 times daily.
2.Max. 60gm per week.
Side effect
Burning, itching, irritation, dryness, folliculitis, hypertrichosis,
acneiform eruptions and hypopigmentation may occur rarely.
Precautions
1.Prolonged use of corticosteroid preparations may
produce striae or atrophy of the skin or subcutaneous
tissue. If this occurs, treatment should be discontinued.
2.If irritation, sensitization, excessive dryness, or
unwanted scaling develop treatment should be
discontinued.
3.Application over extensive lesions may result in
significant systemic absorption producing
hypercortisonism manifesting.
4.If an overt infection is present, appropriate antimicrobial
treatment is indicated.
5.If symptomatic response is not noted within a few days
to a week, the local application should be discontinued.
6.The safety of topical corticosteroid use in preg